Antioxidant of Pleurotus ostreatus (Jacq.) P. Kumn and lymphoid cancer cells

Pk, Md. Moyen Uddin; O'Sullivan, Jane; Pervin, Rumana; Rahman, Matiar

doi:10.1016/b978-0-12-819547-5.00038-9

Cited by 1 publication

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many cultures it is popular to use herbs to treat malignancies, as there are the plenty of anti-cancer compounds in some plants and are used in the manufacture of various modern drugs(4). Different sources of polysaccharides for their anti-cancer activities have been identified(5, 6). Through its possible biological functions, antioxidant(7), anti-tumor(8) and hepatoprotective effects(9), polysaccharides have attracted a lot of attention.…”

Section: Introductionmentioning

confidence: 99%

An Antioxidant Polysaccharide from Ganoderma lucidum Induces Apoptotic Activity in Breast Cancer Cell Line

Pervin

Biswas

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

The purpose of this study is to elucidate the apoptotic activity of Ganoderma lucidum polysaccharide (GLP) in a human breast cancer cell line MCF-7 in vitro. According to DPPH assay, GLP showed a good antioxidant (IC 50 value is 202.4 µg/mL). Based on MTT assay, the results showed that GLP inhibits MCF-7 cells proliferation in a dose- and time- dependent manner (p<0.001). IC 50 values of the cytotoxicity of GLP and doxorubin were 110.907 µg/mL and 58.206 µg/mL respectively. The results from the flow cytometry indicated that GLP could induce apoptotic activity through inducing the up-regulation of the Bax and Caspase-9 and the down-regulation of the BcL-2 in MCF-7 cells. At 2×IC 50 , GLP increased the early-apoptotic and dead cells of MCF-7 from 18.23% to 34.76% and 8.45% to16.34% respectively. In conclusion, the GLP shows anticancer activity against MCF-7 through preventing the proliferation and inducing the apoptosis of MCF-7 cells. Our data provide the potential molecular targets in cancer prevention and reveal the key barriers in the current anticancer drugs development.

show abstract